Pharmacogenetic Predictors of Chemotherapy Treatment-Related Toxicities in Paediatric and Adolescent Acute Lymphoblastic Leukemia: A Systematic Review, Meta-Analysis and Literature-Based Candidate Prioritization
Aug 2026· Pharmaceuticals· Vol 19, pp. 1204· 0 citations· 132 references
Medicine
TL;DR
The review supports routine TPMT and NUDT15 genotyping and highlights the need for harmonised definitions, multi-ethnic studies, standardised data representation, and prospective validation of identified variants, which remains to be evaluated prospectively.
Abstract
Background: Childhood and adolescent acute lymphoblastic leukemia (ALL) survival outcomes have improved significantly, but treatment-related toxicities (TRTs) remain a major concern affecting dose intensity and quality of life. Germline pharmacogenetic variations contribute to inter-individual differences in chemotherapy response, yet consistent replication of associations has been limited by differences in treatment protocols, ethnic backgrounds, and toxicity definitions. Methods: This systematic review and meta-analysis (PROSPERO CRD42021229748) included 68 studies in the qualitative synthesis, with 42 high-quality studies undergoing structured synthesis and, where appropriate, quantitative meta-analysis. Studies focused on the toxicities of thiopurines, methotrexate, glucocorticoids, vincristine, and asparaginase. Results: Meta-analyses showed strong evidence linking the NUDT15 rs116855232 variant to thiopurine-induced myelosuppression (OR 19.0, 95% CI 1.6–224; I2 = 86.5%) and a significant association between the TYMS enhancer repeat polymorphism and osteonecrosis (OR 6.66, 95% CI 3.67–12.11; I2 = 0%). In contrast, MTHFR variants and VDR polymorphisms showed no significant associations with methotrexate-induced myelosuppression or osteonecrosis, respectively. Narrative synthesis highlighted clinically actionable associations: TPMT and NUDT15 with thiopurine toxicity; CEP72 with vincristine neuropathy; and HLA haplotypes with asparaginase hypersensitivity. Population allele frequency comparisons (IndiGenomes, gnomAD, UK Biobank) showed strong concordance (r = 0.919–0.997), supporting the broad generalisability of identified variants, which remains to be evaluated prospectively. The main limitations included heterogeneous toxicity definitions, non-uniform genetic models, evolving treatment protocols, population heterogeneity, and a lack of harmonised reporting. Conclusions: The review supports routine TPMT and NUDT15 genotyping and highlights the need for harmonised definitions, multi-ethnic studies, standardised data representation, and prospective validation. A literature-based candidate gene list for future PGx association studies was generated.
All treatment is becoming more personalized and increasingly guided by immunotherapy, molecular targets, and MRD, although resistance, immune toxicity, transplantation decisions, cost, and unequal access remain important barriers.
Karolina Skórka, Oliwia Żmuda, Natalia Skórka et al.· International Journal of Inn...· 0 citations
Acute lymphoblastic leukemia (ALL), the most common childhood cancer, shows >90% survival in high-income settings but poorer outcomes in low- and middle-income regions due to increased infection rates, toxicity, and treatment abandonment. This single-center retrospective study from January 2016 to June 2025, analyzed o...
Surabhi Pokhariyal, Sohini Chakraborty, S. Arora et al.· Leukemia and Lymphoma· 0 citations
Acute lymphoblastic leukemia (ALL) non-Philadelphia chromosome–positive (non-Ph+) is a major subtype of leukemia with high relapse rates and significant toxicity from conventional chemotherapy. This study evaluated the efficacy and safety of targeted therapy versus chemotherapy in non-Ph+ ALL. This systematic review an...
D. N. N. Karyana, Fadhilla Resendryana Esthya, I. N. Diarsa· Indonesian Journal of Life S...· 0 citations
Pediatric ALL protocols in Uzbekistan had the lowest overall costs, Kazakhstan included a broader range of targeted therapies with intermediate costs, and Russia had the highest costs.
Umarova Shakhnoz Ziyatovna, Rakhmonova Gulhayo Avazbekovna, Pulatova Nargiza Sirojiddinovna et al.· Iranian Journal of Pediatric...· 0 citations
An ethnicity-based benchmarking analysis of therapeutic outcomes across standard-of-care ICI combination regimens demonstrates consistent clinical efficacy across Asian and Caucasian populations, with no statistically significant or clinically meaningful divergence in ORR or PFS.
D. Khanna, T. Dey, E. Blanchard-Cavagis et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.